SCHEMBL28467446

SCHEMBL28467446

CC1(C)NCC(C(N)=O)(C(F)(F)F)O1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21078730 1.00 GAA (0.32) GAA
SCHEMBL21304073 1.00 GAA (0.32) GAA
SCHEMBL29183099 0.70 GAA (0.31) GAA
SCHEMBL22732857 0.69 DGAT1 (0.31)
SCHEMBL16056817 0.68 DGAT1 (0.32)
SCHEMBL30008546 0.62
SCHEMBL23575974 0.60 MEN1 (0.34)
SCHEMBL32667735 0.55 PKM (0.37)
SCHEMBL17164996 0.55 GAA (0.41) GAA
SCHEMBL1515542 0.54 DGAT1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275724-B2 Processes and intermediates for the preparation of soluble guanylate cyclase stimulators CYCLERION THERAPEUTICS, INC. (US) 2025-04-15 US disclosed
US-20240391911-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS CYCLERION THERAPEUTICS, INC. 2024-11-28 US disclosed
CN-118221665-A Methods and intermediates for preparing soluble guanylate cyclase stimulators 赛克里翁治疗有限公司 2024-06-21 CN disclosed
CN-118184645-A Methods and intermediates for preparing soluble guanylate cyclase stimulators 赛克里翁治疗有限公司 2024-06-14 CN disclosed
CN-111902410-B Methods and intermediates for preparing soluble guanylate cyclase stimulators 赛克里翁治疗有限公司 2024-04-19 CN disclosed
CN-111712247-B sGC stimulators 塞科里昂医疗股份有限公司 2024-02-09 CN disclosed
CN-109563086-B Process for preparing soluble guanylate cyclase stimulators 赛克里翁治疗有限公司 2023-05-23 CN disclosed
CN-111902410-A Novel process and intermediates for the preparation of soluble guanylate cyclase stimulators 赛克里翁治疗有限公司 2020-11-06 CN disclosed
CN-111712247-A sGC stimulators 塞科里昂医疗股份有限公司 2020-09-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275724-B2 Processes and intermediates for the preparation of soluble guanylate cyclase stimulators GUCY1A2, GUCY1B1, GUCY1B2 GAA 1412/4885
US-20240391911-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS GUCY1A2, GUCY1B1, GUCY1B2 GAA 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.